Malignancy-associated lower-extremity deep vein thrombosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Participants aged 18 years or older with a confirmed DVT and a clinical diagnosis of malignant tumor or benign tumor were eligible for inclusion.. 2.An anticipated follow-up period of at least 6 months is required. 3. Diagnosis of cancer-associated DVT was confirmed by medical history or other diagnostic tests related to malignant tumors;
Exclusion criteria
Exclusion criteria: 1. Participants who have received anticoagulation, immunosuppressive therapy, or hematologic system–related treatment within the last 3 months are excluded. 2.Participants who cannot be diagnosed as cancer-associated DVT based on medical history or other diagnostic indicators are excluded. 3. Participants with severe infection, autoimmune disease, or pregnancy are excluded. 4.Participants who have experienced brain infarction, myocardial infarction, or cerebrovascular accident within the last 3 months are excluded.5.Severe trauma within the past 4 weeks, recent major surgery, or other reliable ancillary examinations indicating contraindications lead to exclusion. 5.Severe trauma within the past 4 weeks, recent major surgery, or other reliable ancillary examinations indicating contraindications lead to exclusion. 6.Participants with coagulation disorders or severe cardiopulmonary insufficiency or severe dysfunction of other critical organs are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differential expression levels of peripheral blood proteins between cancer-associated DVT patients and non-cancer DVT patients; | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnostic performance of candidate biomarkers (AUC, sensitivity, specificity); | — |
Countries
China
Contacts
The First Affiliated Hospital of Anhui Medical University